FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306367253> ?p ?o ?g. }

• W4306367253 endingPage "4949" @default.
• W4306367253 startingPage "4930" @default.
• W4306367253 abstract "Our group developed a new model of drug combination consisting of the use of antineoplastic drugs and different repurposed drugs, having demonstrated that antimalarial and central nervous system (CNS) drugs have a promising anticancer profile as standalone agents, as well as in combined regimens. Here, we evaluated the anticancer profiles of two different CNS drugs (edaravone and quetiapine), both alone and in combination with antineoplastic agents for breast and colon cancer, to explore whether these repurposed drugs could synergistically enhance the anticancer potential of chemotherapeutic drugs. We also developed a new model of combination using two repurposed drugs, to explore whether this model of combination could also be suitable for application in breast and colon cancer therapy. MCF-7 and HT-29 cancer cells were incubated for 48 h with each individual drug (0.01–100 µM) to determine their IC50. Cells were then treated with the IC50 value for doxorubicin or paclitaxel (MCF-7) or 5-fluorouracil (HT-29) and combined with increasing concentrations of edaravone or quetiapine for 48 h. Both cell lines were also treated with a combination of two antimalarial drugs (mefloquine and pyronaridine) or two CNS drugs (fluphenazine and sertraline) for 48 h. We found that the use of quetiapine in combined therapies seems to synergistically enhance the anticancer activity of doxorubicin for the management of breast cancer. Both CNS drugs significantly improved the cytotoxic potential of 5-fluorouracil in HT-29 cells, with quetiapine synergistically interacting with the antineoplastic drug in this drug combination. Regarding the combination of repurposed drugs, only found one synergic combination regimen (sertraline IC50 plus variable concentrations of fluphenazine) with anticancer potential against HT-29 colon cancer cells was found. Taken together, these results suggest that quetiapine and edaravone can be used as adjuvant agents in chemotherapy for colon cancer. It was also found that the combination of repurposed drugs, specifically the CNS drugs sertraline and fluphenazine, may have an interesting profile for application in colon cancer novel therapies." @default.
• W4306367253 created "2022-10-17" @default.
• W4306367253 creator A5004830875 @default.
• W4306367253 creator A5027669049 @default.
• W4306367253 creator A5054091339 @default.
• W4306367253 date "2022-10-16" @default.
• W4306367253 modified "2023-10-14" @default.
• W4306367253 title "Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells" @default.
• W4306367253 cites W1993748684 @default.
• W4306367253 cites W2006452977 @default.
• W4306367253 cites W2008036752 @default.
• W4306367253 cites W2015088299 @default.
• W4306367253 cites W2015360869 @default.
• W4306367253 cites W2050192803 @default.
• W4306367253 cites W2051101274 @default.
• W4306367253 cites W2060802427 @default.
• W4306367253 cites W2062941476 @default.
• W4306367253 cites W2096439168 @default.
• W4306367253 cites W2115933266 @default.
• W4306367253 cites W2135215861 @default.
• W4306367253 cites W2165635928 @default.
• W4306367253 cites W2165921162 @default.
• W4306367253 cites W2231123802 @default.
• W4306367253 cites W2260188081 @default.
• W4306367253 cites W2317055602 @default.
• W4306367253 cites W2399140686 @default.
• W4306367253 cites W2556932167 @default.
• W4306367253 cites W2601374730 @default.
• W4306367253 cites W2603616104 @default.
• W4306367253 cites W2617112080 @default.
• W4306367253 cites W2734327577 @default.
• W4306367253 cites W2735892091 @default.
• W4306367253 cites W2761631067 @default.
• W4306367253 cites W2769673456 @default.
• W4306367253 cites W2800454843 @default.
• W4306367253 cites W2941444700 @default.
• W4306367253 cites W2944386491 @default.
• W4306367253 cites W2945135792 @default.
• W4306367253 cites W2947719500 @default.
• W4306367253 cites W2981801661 @default.
• W4306367253 cites W2986525678 @default.
• W4306367253 cites W2990791883 @default.
• W4306367253 cites W3002246501 @default.
• W4306367253 cites W3046124964 @default.
• W4306367253 cites W3092892781 @default.
• W4306367253 cites W3110259941 @default.
• W4306367253 cites W3118965229 @default.
• W4306367253 cites W3119005666 @default.
• W4306367253 cites W3177769843 @default.
• W4306367253 cites W4206841660 @default.
• W4306367253 cites W4214562326 @default.
• W4306367253 cites W4220718289 @default.
• W4306367253 cites W4224323967 @default.
• W4306367253 doi "https://doi.org/10.3390/cimb44100335" @default.
• W4306367253 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36286050" @default.
• W4306367253 hasPublicationYear "2022" @default.
• W4306367253 type Work @default.
• W4306367253 citedByCount "1" @default.
• W4306367253 countsByYear W43063672532023 @default.
• W4306367253 crossrefType "journal-article" @default.
• W4306367253 hasAuthorship W4306367253A5004830875 @default.
• W4306367253 hasAuthorship W4306367253A5027669049 @default.
• W4306367253 hasAuthorship W4306367253A5054091339 @default.
• W4306367253 hasBestOaLocation W43063672531 @default.
• W4306367253 hasConcept C118552586 @default.
• W4306367253 hasConcept C121608353 @default.
• W4306367253 hasConcept C126322002 @default.
• W4306367253 hasConcept C2776412080 @default.
• W4306367253 hasConcept C2776694085 @default.
• W4306367253 hasConcept C2776999253 @default.
• W4306367253 hasConcept C2777292972 @default.
• W4306367253 hasConcept C2780035454 @default.
• W4306367253 hasConcept C2780634440 @default.
• W4306367253 hasConcept C2781303535 @default.
• W4306367253 hasConcept C526805850 @default.
• W4306367253 hasConcept C530470458 @default.
• W4306367253 hasConcept C71924100 @default.
• W4306367253 hasConcept C98274493 @default.
• W4306367253 hasConceptScore W4306367253C118552586 @default.
• W4306367253 hasConceptScore W4306367253C121608353 @default.
• W4306367253 hasConceptScore W4306367253C126322002 @default.
• W4306367253 hasConceptScore W4306367253C2776412080 @default.
• W4306367253 hasConceptScore W4306367253C2776694085 @default.
• W4306367253 hasConceptScore W4306367253C2776999253 @default.
• W4306367253 hasConceptScore W4306367253C2777292972 @default.
• W4306367253 hasConceptScore W4306367253C2780035454 @default.
• W4306367253 hasConceptScore W4306367253C2780634440 @default.
• W4306367253 hasConceptScore W4306367253C2781303535 @default.
• W4306367253 hasConceptScore W4306367253C526805850 @default.
• W4306367253 hasConceptScore W4306367253C530470458 @default.
• W4306367253 hasConceptScore W4306367253C71924100 @default.
• W4306367253 hasConceptScore W4306367253C98274493 @default.
• W4306367253 hasIssue "10" @default.
• W4306367253 hasLocation W43063672531 @default.
• W4306367253 hasLocation W43063672532 @default.
• W4306367253 hasLocation W43063672533 @default.
• W4306367253 hasOpenAccess W4306367253 @default.
• W4306367253 hasPrimaryLocation W43063672531 @default.

• next